

**Myelo Therapeutics is selected as one of four companies worldwide to participate in Elsevier's incubator project.**

Berlin, Jan 13<sup>th</sup>, 2017 – Myelo Therapeutics GmbH announced today that it was selected as one of four companies worldwide for *The Hive*, Elsevier's new incubator project for biotech and pharmaceutical start-up firms.

Myelo Therapeutics was chosen for its commitment to addressing areas of high unmet patient needs with its lead development candidate Myelo001, a new, innovative adjuvant cancer therapy for the treatment for Chemotherapy-induced Neutropenia (CIN). The Myelo Therapeutics research team will receive complimentary training and access to Elsevier's suite of information solutions, to empower ongoing research activities.

Through *The Hive*, Elsevier will showcase the innovation that occurs in early stage drug discovery and development. *"The goals of The Hive are to highlight the incredible innovation taking place in the pharmaceutical and biotech space and the important role that small biotech start-ups play in the origin of drug discoveries,"* said Alexander Van Boetzelaer, Managing Director, Elsevier's R&D Solutions. *"The four companies we selected for The Hive are exceptional examples of the kind of cutting-edge research that is happening in the industry. We believe that each one has the potential to drive successful pharmaceutical outcomes and improve the lives of patients. We are delighted to welcome these four companies to The Hive and look forward to sharing their stories."*

*"Our research has generated a wealth of data, indicating efficacy of Myelo001 not only in the prophylaxis of Chemotherapy-induced Neutropenia, but also in potentially preventing Radiation-induced Neutropenia, as well as a broad range of viral infections"* says Patrik Brehm, Preclinical Research Manager at Myelo Therapeutics. *"With access to the wealth of data provided by Elsevier's information solutions, we expect to significantly accelerate our research activities"*.

**About Chemotherapy-induced Neutropenia (CIN):**

Cytotoxic chemotherapy frequently suppresses the hematopoietic system, impairing host protective mechanisms. Chemotherapy-induced Neutropenia (CIN), the most serious hematologic toxicity, is associated with the risk of life-threatening infections. As a consequence of such an infection it can become necessary to reduce dosage of or delay chemotherapy, which may compromise treatment outcomes.  
<http://www.ncbi.nlm.nih.gov/pubmed/14716755>

**About Myelo001:**

Myelo001 is a new, innovative adjuvant cancer therapy for the treatment for CIN. In preclinical and first clinical studies, Myelo001 has shown to be well tolerated and effective in reducing the risk of CIN in patients across various cancer types and chemotherapy regimens. In addition, Myelo001 possesses antiviral properties, an additional benefit in immunosuppressed patients treated with chemotherapy. Myelo001 is taken orally, starting treatment prior to chemotherapy.

<https://clinicaltrials.gov/ct2/show/NCT02692742>

[http://www.myelotherapeutics.com/news\\_files/Myelo001\\_Abstract\\_MASCC\\_2015.pdf](http://www.myelotherapeutics.com/news_files/Myelo001_Abstract_MASCC_2015.pdf)



ELSEVIER

About Myelo Therapeutics GmbH:

Myelo Therapeutics is a pharmaceutical company based in Berlin and Dresden, Germany, that is developing innovative treatments in areas of high unmet medical needs. For more information, visit [www.myelotherapeutics.com](http://www.myelotherapeutics.com).

Contact: Myelo Therapeutics GmbH; Till Erdmann, Kastanienallee 56; 10119 Berlin, Germany  
Phone: +49 (0) 170 9126 402; [info@myelotherapeutics.com](mailto:info@myelotherapeutics.com)

About The Hive:

The Hive is a collaboration project through which Elsevier R&D Solutions works with a select group of biotech and pharmaceutical start-ups to raise the visibility of their work in early stage drug discovery and development research and share lessons in overcoming pharma R&D challenges.

About Elsevier:

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make ground-breaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. [www.elsevier.com](http://www.elsevier.com)

Contact: Christopher Capot, Director, Corporate Relations Elsevier. Phone +1 917-704-5174.  
Email [c.capot@elsevier.com](mailto:c.capot@elsevier.com). [www.elsevier.com](http://www.elsevier.com)